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1. ABSTRACT  
Diabetes mellitus is considered a risk factor for Group B Streptococcus (GBS) 
infections. Typically, this pathology is associated to high glucose levels in the 
bloodstream. Although clinical evidences support this notion, the physiological 
mechanisms underlying GBS adaptation to such conditions are not yet defined. In 
the attempt to address this issue, we performed comparative global gene 
expression analysis of GBS grown under glucose-stress conditions and observed 
that a number of metabolic and virulence genes was differentially regulated. Of 
importance, we also demonstrated that by knocking-out the csrRS locus the 
transcription profile of GBS grown in high-glucose conditions was profoundly 
affected, with more than a third of glucose-dependent genes, including the 
virulence factor bibA, found to be controlled by this two-component system. 
Furthermore, in vitro molecular analysis showed that CsrR specifically binds to 
the bibA promoter and the phosphorilation increases the affinity of the regulator to 
this promoter region. Moreover, we demonstrated that CsrR acts as a repressor 
of bibA expression by binding to its promoter in vivo. In conclusion, this work by 
elucidating both the response of GBS to pathological glucose conditions and the 
underlined molecular mechanisms will set the basis for a better understanding of 
GBS pathogenesis. 
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2. INTRODUCTION 
2.1 Group B Streptococcus  
Streptococcus agalactiae, also named Group B Streptococcus or GBS, is an 
encapsulated Gram positive coccus. In 1933, Rebecca Lancefield identified the 
group B antigen, a cell wall-associated carbohydrate that distinguishes GBS from 
other streptococcal species (Lancefield, 1934). It forms small 3 to 4 mm, grey-
white colonies that have a narrow zone of beta hemolysis on blood agar plate. 
GBS strains are classified into ten serotypes according to immunogenic 
characteristics of the capsule polysaccharides (Ia, Ib, II, III, IV, V, VI,VII, VIII and 
IX). Approximately 10% of serotypes are non-typeable (Kong et al., 2002; 
Bisharat et al., 2005; Gherardi et al., 2007; Skoff et al., 2009) 
GBS is principally a microbe of bovine and human origin although strains have 
been isolated from fish, dogs, piglets and occasionally from other animal species. 
There is no definitive evidence that infected cattle serve as a reservoir for transfer 
of the Group B Streptococcus to human. Indeed different studies have 
demonstrated biochemical, biological and serological differences between bovine 
and human strains. 
Group B organisms were only rarely considered as agents of human infections 
while recognized as commensals among the normal flora of human upper 
respiratory tract and the female genitourinary tract. More than 30 years ago, the 
attention to Group B Streptococcus as a major cause of neonatal sepsis 
dramatically increased. In that period, in fact, half of the patients with GBS 
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infection died. Up to now, remain unclear the reason for the emergence of Group 
B Streptococci as etiological agent of neonatal disease. 
 
 
 
 
  
2.2 Epidemiology of GBS 
Group B Streptococcus colonizes the urogenital tract of more 30% of the healthy 
population and in particular it colonizes the vagina of 25-40% of healthy women 
(Dillon et al., 1982; Schuchat, 1998; Hansen et al., 2004). It has been found in the 
urethra in both men and women without causing infections and in the upper 
respiratory tract. Colonization also is observed in wound and soft tissue cultures 
in the absence of obvious infection. Determining the acquisition and transmission 
of S. agalactiae can be puzzling, as it is very invasive but produces little 
inflammation at the entry site. 
This bacterium is an important cause of infection in three populations: 
 Pregnant women  
Figure 2.1 Streptococcus agalactiae. (A) Scanning Electron Microscopy (SEM) of 
Streptococcus agalactiae. (B) Colonies Streptococcus agalactiae on a blood agar plate. Note 
the zone of clear haemolysis. 
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 Neonates 
 Nonpregnant adults 
GBS causes a variety of perinatal infections in pregnant women, including both 
symptomatic and asymptomatic bacteriuria, endometritis, amnionitis, meningitis, 
pyelonephritis, and post partum wound infections (Pass et al., 1982). It also has 
been suggested that GBS urinary tract infections or urinary tract, rectal, or genital 
colonization in pregnant woman may lead to late term abortions and preterm and 
low-birth-weight infants. Pregnant women are colonized at multiple sites, 
including rectum, vagina, cervix and throat, but many of them carry GBS in 
asymptomatically way (Regan et al., 1991). However, GBS colonization in 
pregnant women is important because of the risk for transmission to their 
newborns. Most infections and colonization of newborns are due to aspiration of 
contaminated vaginal and amniotic fluid before or during parturition (Doran & 
Nizet, 2004). This pathogen is the leading cause of neonatal bacterial diseases in 
the United States of America; infection in newborns has been divided in early-
onset disease (EOD) and late-onset disease (LOD) depending on the infants’ age 
and disease manifestations. Infants with EOD most commonly have sepsis or 
pneumonia while meningitis and bone and soft tissue infections can also occur 
(Edwards, 2001; Puopolo et al., 2005). LOD is less frequent than EOD and the 
mortality rate is lower. In contrast morbidity is high, as around 50% of neonates 
that survive to GBS infection suffer complication, including mental retardation, 
hearing loss and speech and language delay (Schuchat, 1998; Schrag et al., 
2000; Edwards, 2001). 
Although GBS is commonly associated with neonatal diseases (Johri et al., 2006) 
and thought of as causes of disease in pregnant women, it causes substantial 
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morbidity and mortality among non pregnant adults (Fig. 2.2) and appears to be 
increasing in incidence in that population. 
 
 
 
 
The reported annual incidence of GBS infection in nonpregnant adults in the 
general population is between 4 and 7 per 100,000 (Schrag et al., 2000; Zangwill 
et al., 1992 Farley et al., 1993; Blumberg et al., 1996; Phares et al., 2008; Skoff et 
al., 2009). However, the risk is as high as 26 per 100,000 in patients ≥65 years of 
age (Schrag et al., 2000; Phares et al., 2008). This risk reflects an increase in 
incidence between 1999 and 2005 in a population-based surveillance study in ten 
states in the United States (Phares et al., 2008). In view of the reductions in GBS 
infection in neonates and pregnant women, GBS infection in adults is now 
estimated to account for over three-fourths of invasive GBS disease in the United 
States and for 90 percent of the mortality. At least 1300 GBS-related deaths 
Figure 2.2 Incidence of invasive Group B streptococcal disease by age (case per 100000) 
(open bars) and case fatality ratio (%) (Black line) in person > 18 years of age (Gram-positive 
pathogens - Vincent A. Fischetti ,American Society for Microbiology, 2006). 
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occurred among elderly persons in 2003; the case fatality rate for elderly adults is 
estimated at 15 percent (Edwards and Baker, 2005). 
Of ten known GBS serotypes, the most commons reported among adults are 
types Ia, III and V. A population- based study found serotype V to be the most 
common one causing disease in non pregnant adults and the second most 
common serotype in pregnant women (Harrison et al., 1998); in fact more than 
25% of the subjects had invasive GBS disease caused by type V strains (Table 
2.1).  
Table 2.1 Serotype distribution of Group B streptococcal isolates  from non-pregnant adults with 
invasive GBS infection, 1992-1999 ( Edward and Baker, 2005). 
. 
 
 
 
 
 
 
 
 
 
  GBS serotype 
N° (%) of 
subjects 
(n=589) 
Ia 143 (24.3) 
Ib 72 (12.2) 
II  70 (11.9) 
III 97 (16.5) 
IV 2 (0.3) 
V 162 (27.5) 
VI 0 
VII 0 
VIII 1 (0.2) 
Non-typeable 42 (7.1) 
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Numerous studies have allowed description of the clinical spectrum of disease, 
including clinical features, risk factors, therapy, and outcomes. The most common 
syndromes caused by GBS in adults are skin, soft tissue, and bone infections. 
These infections are often complications of chronic diabetes or decubitus ulcer. 
Cellulitis, foot ulcers, and abscesses are the most common manifestation, but 
also necrotizing fasciitis have occasionally been reported (Edwards and Baker, 
2005). Patients with indwelling catheters are at higher risk for GBS bacterimia; 
polymicrobial bacteremia, often with Staphylococcus aureus is identified in 26 to 
30% of patients with GBS colonization (Jackson et al., 1995). GBS can also 
cause pneumonia, increasing the mortality rate of patients. Less common GBS 
infections such as arthritis, urinary infection, meningitis, and peritonitis can also 
occur, especially in patients with common predisposing factors, such as diabetes, 
osteoarthritis, and underlying joint disease. S agalactiae infection is extremely 
rare in healthy individuals and is almost always associated with underlying 
abnormalities. Risk factors that promote GBS infections include diabetes mellitus, 
elderly, malignancy, liver disease, neurological deficits, renal failure, other forms 
of immune impairment such as human immunodeficiency virus infection, cancer 
and venous insufficiency (Jenkins et al., 2010). 
Elderly patients with diabetes mellitus have displayed peripheral neuropathy or 
peripheral vascular diseases following trauma, particularly to the lower 
extremities. GBS takes advantage of this condition by crossing the endothelial 
barrier and promoting bacterial invasion of the foot (Edwards and Baker, 2005). 
Indeed, GBS is also found in biopsy of patients with foot infections, a common 
status of patients suffering from diabetes (Urban et al., 2011). Group B 
streptococcal infection in elderly people (≥70 years) is strongly linked to 
8 
 
congestive heart failure and being bedridden, with urinary tract infection, 
pneumonia, and soft-tissue infection as the most common manifestations of 
infection. Neurologic illness is associated with pneumonia in elderly people, 
possibly due to aspiration of Group B Streptococci from the upper respiratory 
tract.  
2.3 Molecular pathogenesis of GBS 
Group B Streptococcus infection in human is a complex and multifactorial process 
which involves several virulence determinants that contribute to neonatal disease. 
An important role is mediated by the capsule, which remains together to the β-
haemolytic activity the main virulence factor for Group B Streptococcus. In 
addition, a number of molecules both surface-exposed or secreted are necessary 
for GBS infection process (Table 2.2). 
The GBS pathogenic process can be described in four main steps:  
A. Colonization of mucosal surfaces; 
B. Translocation through host cellular barriers; 
C. Evasion of immunological clearance; 
D. Activation of inflammatory response. 
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A. Colonization of mucosal surfaces 
GBS adheres to a variety of human cells including vaginal, intestinal and 
respiratory tract epithelium, blood–brain barrier endothelium and placental 
membranes. In particular GBS behaves as a commensal organism that colonizes 
the lower gastrointestinal and genital tracts of healthy adults occupying a niche 
that places infants at risk of vertical transmission. The interaction between GBS 
and epithelial cells is mediated by several bacterial molecules that interact with 
both low and high affinity with different host cell components (Wibawan et al., 
1992). 
Several studies have demonstrated that GBS is able to interact with the 
extracellular matrix (ECM) components like fibronectin, fibrinogen and laminin. 
Indeed, GBS binds to immobilized fibronectin (Tamura and Rubens, 1995) but not 
to the soluble form (Butler et al., 1987). The GBS fibronectin-binding property 
Figure 2.3 Schematic representation of the molecular and cellular pathogenesis of GBS (Doran 
and Nizet, 2004). 
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seems to be associated with the surface-anchored C5a peptidase, ScpB 
(Beckmann et al., 2002). The binding to fibronectin facilitates mucosal 
colonization and mediates GBS internalization into host cells (Cheng et al., 
2002a). On the other hand, the adherence of GBS to laminin involves the laminin 
binding protein, Lmb (Spellerberg et al., 1999), while attachment of GBS to 
fibrinogen is mediated by two unrelated surface fibrinogen binding protein, FbsA 
and FbsB (Gutekunst et al., 2004; Schubert et al., 2002). GBS binding to 
fibrinogen and fibronectin is positively regulated by the transcriptional regulator 
RogB, which modulates the expression of a number of genes coding ECM 
binding proteins (Gutekunst et al., 2003). The recently described pilus-like 
structures present on the surface of GBS (Lauer et al., 2005) also seems to be 
involved in the adherence of bacteria to lung epithelial cells. In particular the 
knock-out mutant strain for the ancillary protein shows an impaired ability to 
adhere to epithelial cells (Maisey et al., 2006). 
B. Translocation through host cellular barriers 
The strategy used by GBS to traverse defined anatomic epithelial barriers, such 
as the cervical or vaginal epithelium, entering bloodstream is still poorly 
understood. However, the GBS ability to penetrate host cellular barriers is the first 
distinguishing feature of its pathogenicity.  
GBS has the ability to invade chorionic but not amniotic epithelial cells (Winram et 
al., 1998). Nevertheless, GBS can traverse placental membranes, weak their 
tensile strength and access to the fetus within the amniotic cavity. This process 
induces placental membrane rupture or trigger premature delivery. After 
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aspiration of infected amniotic or vaginal fluid, the initial focus of GBS infection 
takes place in the newborn lung. From there, the organism rapidly gains access 
to the bloodstream and is circulated through other organs and tissues.  
GBS has the ability to invade both alveolar epithelial and pulmonary endothelial 
as initially noted in newborn macaques (Rubens et al., 1991), and later confirmed 
in human tissue culture lines derived from both cellular barriers (Gibson et al., 
1993; Rubens et al., 1992). Cellular invasion by GBS occurs when the organism 
triggers its own endocytotic uptake and enters the cell within a membrane-bound 
vacuole. In the host, this process requires rearrangement of microfilament 
components of the cytoskeleton and the signalling pathways mediated by PI 3-
kinase, seem to be involved (Tyrrell et al., 2002). 
There is a close correlation between cellular invasion and GBS virulence 
potentiality because clinical isolates from infants with bloodstream infections 
invade epithelial cells better than strains from the vaginal mucosa of 
asymptomatic women (Valentin-Weigand and Chhatwal, 1995). Other proteins 
like ScpB or the alpha C surface protein are involved in GBS epithelial cell 
invasion (Bolduc et al., 2002; Cheng et al., 2002b).  
Early-onset GBS pneumonia is characterized by widespread damage to lung 
epithelium and endothelium, with haemorrhage and neutrophils entering the 
alveolar airspaces. GBS enters the bloodstream as a consequence of the loss of 
barrier integrity and the β-haemolysin/cytolysin (β-H/C) appears the protein 
largely involved in this process. cylE is the gene necessary and sufficient for GBS 
β-H/C expression (Pritzlaff et al., 2001). This pore-forming toxin lyses lung 
epithelial and endothelial cells and compromises their barrier function (Gibson et 
al., 1999; Nizet et al., 1996). Besides, the GBS β-H/C promotes GBS intracellular 
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invasion and triggers the release of interleukin-8 (IL-8) that is the principal 
chemoattractant for human neutrophils (Doran et al., 2002). 
GBS is also the leading cause of bacterial meningitis in human newborns and the 
bacterium has the propensity to breech the specialized endothelium comprising 
the human blood–brain barrier. In fact, it has been reported that COH1, a highly 
encapsulated GBS strain, was able to invade and translocate across a polarized 
brain microvascular epithelial cell monolayer without marked changes in 
transendothelial electrical resistance (Nizet et al., 1997). As for the epithelial cell 
barriers, the GBS β-H/C is directly cytolytic for human brain endothelial cells 
(Doran et al., 2003).  
GBS virulence factors play a pivotal role in penetration of host cellular barriers. It 
is reported that bloodstream isolates of GBS secrete high levels of an enzyme 
that degrades hyaluronic acid, the main polysaccharide component of host 
connective tissue (Kjems et al., 1980; Pritchard and Cleary, 1996). Another 
important extracellular protein involved in invasion is CAMP factor; this protein 
oligomerizes in the target membrane to form discrete pores and triggers cell lysis 
(Lang and Palmer, 2003) and it is toxic when injected intravenously in rabbits 
(Skalka and Smola, 1981).  
Recently, it has been proposed a novel paracellular route used by GBS to 
traverse epithelial cells monolayer. In this new model, the crossing of bacteria 
across the cell is not associated with the loss of monolayer’s integrity suggesting 
that paracellular translocation is likely to be an active but transient phenomenon 
used by GBS to translocate from the site of colonization to target organs (Soriani 
et al., 2006). 
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C. Evasion of immunological clearance 
Phagocytic cells including polymorphonucleates (PMNs) and macrophages are 
the first line of defence against GBS and their early action determines to outcome 
of the infection. However, the effective uptake and killing of GBS by these cells 
requires opsonization of the bacterium and deposition of complement 
components (Jarva et al., 2003). Neonates that are deficient in a) phagocytic cell 
function, b) specific anti-GBS immunoglobuling and c) classic and alternate 
complement components, are also particularly prone to GBS invasive disease.  
Polysaccharide capsule is fundamental to the avoidance of immune response. 
Indeed, sialylated GBS capsule protects the bacterium by PMNs mediated 
opsonophagocytic killing, preventing C3 deposition on the bacterial surface. 
Isogenic GBS mutant defected for capsule synthesis is more susceptible to killing 
by PMNs. As a consequence, lethal doses of capsule-deficient strains are in mice 
100-fold greater than the one of the parental wild-type strain (Marques et al., 
1992; Wessels et al., 1989).  
Other multifunctional GBS determinants that contribute to bacterial resistance to 
the host clearance mechanisms have been identified (Jarva et al., 2003). Among 
them, FbsA seems to be important for the survival of bacteria in human blood 
(Schubert et al., 2002). The beta-C protein binds the Fc domain of human IgA, 
potentially sequestering this important host mucosal defence molecule (Jerlstrom 
et al., 1996), while GBS strains expressing the alpha-C protein appear more 
resistant to phagocytic killing (Madoff et al., 1991).  Besides, the presence of 
tandem repeats within the alpha C sequence is correlated to antigenic variability 
that allows the bacterium to avoid opsonophagocytic killing triggered by specific 
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antibody (Madoff et al., 1996). The C5a-ase possesses a domain that specifically 
cleaves human complement component C5a, a chemoattractant for human 
PMNs, reducing the acute neutrophils response to sites of infection (Bohnsack et 
al., 1997). A recently identified novel cell surface protease named CspA targets 
host fibrinogen, producing adherent fibrin-like cleavage products that coat the 
bacterial surface and interfere with opsonophagocytic clearance (Harris et al., 
2003). 
The application of signature-tagged mutagenesis for in vivo screening in a GBS 
neonatal rat sepsis model has identify unexpected virulence genes encoding 
factors that are crucial for the bacterium survival to immune clearance. For 
example, ponA, which codes for an extracytoplasmic penicillin-binding protein 
(PBP1a), promotes resistance to phagocytic killing independent of capsule (Jones 
et al., 2003) and protects form cationic anti-microbial peptides (defensins, 
cathelicidins) produced by host epithelial cells and phagocytes (Hamilton et al., 
2006). An analogue function is associated with the D-alanylation of lipotechoic 
acid in the bacterial cell wall (Poyart et al., 2003).  
The GBS β-H/C triggers cytolytic events in macrophages and neutrophils (Liu et 
al., 2004) and can also induce macrophage apoptosis (Buratta et al., 2002; Ulett 
et al., 2003) Curiously, GBS has been shown to survive for prolonged periods 
within the phagolysosome of macrophages and to be >10-fold more resistant to 
hydrogen peroxide killing than catalase-positive Staphylococcus aureus (Wilson 
and Weaver, 1985). Superoxide dismutase (SodA) (Poyart et al., 2001) and the 
orange carotenoid pigment (Liu et al., 2004) are the main defences of GBS 
against oxidative stress. Indeed, the pigmentation is a property unique among 
haemolytic streptococci and genetically linked to the cylE gene. Carotenoids 
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neutralize hydrogen peroxide and singlet oxygen, therefore providing a shield 
against the key elements of phagocyte oxidative burst killing (Liu et al., 2004). 
D. Activation of inflammatory responses 
The host inflammatory response to GBS invasive infections, is associated to the 
sepsis syndrome and multiorgan dysfunction. Peptidoglycan and other GBS 
components associated with the cell wall, not including the surface 
polysaccharide capsule, appear to be the most provocative agents in triggering 
host cytokine cascades, in particular the proximal mediators tumour necrosis 
factor-alpha (TNF-α) and interleukin-1 (IL-1). GBS induction of NF-kB signalling 
and TNF-α release from human monocytes in vitro requires CD14 and the 
receptors for complement components 3 and 4 (Medvedev et al., 1998). Recently, 
the importance of complement components in amplifying GBS TNF-α induction 
was corroborated when reduced levels of the cytokine were observed in the blood 
of C3 or C3 receptor-deficient mice stimulated with GBS (Levy et al., 2003). 
Knockout mouse studies indicate GBS cell wall peptidoglycan-induced activation 
of p38 and NF-kB, depends on the cytoplasmic TLR adaptor protein MyD88, but 
does not proceed via the well studied TLR2 and/or TLR4 (Henneke et al., 2002). 
Of interest, GBS β-H/C and cell wall components act synergistically to induce 
macrophage production of inducible nitric oxide synthase (iNOS) and generation 
of nitric oxide (NO) (Ring et al., 2002), a potent factor in  the sepsis cascade. 
LOD is characterized by meningitis with or without accompanying sepsis 
Localization of GBS in the brain and Central Nervous System (CNS) during LOD, 
triggers a strong host inflammatory response. Indeed, in the infant rat model, 
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early GBS meningitis is characterized by acute neutrophilic inflammation in the 
subarachnoid space and ventricles, vasculopathy and neuronal injury. The 
initiation of the CNS inflammatory response is triggered by the blood–brain barrier 
endothelium, which activates a specific pattern of gene transcription for neutrophil 
recruitment, including production of chemokines, endothelial receptors and 
neutrophil activators (Doran et al., 2003). The principal provocative factor for the 
blood–brain barrier inflammatory gene response is the GBS β-H/C, and this toxin 
has also been shown to contribute to the development of meningitis (Doran et al., 
2003).  
Table 2.2 Key virulent factors of Group B Streptococcus (Doran and Nizet, 2004). 
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2.4 Regulation of gene expression 
The GBS pathogenesis implies that this bacterium can survive in a large number 
of human body compartments, encountering different environmental conditions, 
such as different pH, availability of carbon source and temperature. The 
modulation of gene expression allows the adaptation through different 
mechanisms of regulation that control the production of proteins involved in 
adhesion, nutrient acquisition, survival to host immune system (Sitkiewicz et al., 
2009; Mereghetti et al., 2008; Mereghetti et al., 2009). 
A. Two component regulatory system 
One common mechanism used by bacteria to regulate gene expression is the 
alteration of sigma factors associated with RNA polymerase. In light of paucity of 
sigma factors, GBS may rely more on other mechanisms for regulation on gene 
expression. GBS strains generally possess approximately 17-20 predicted two 
component regulatory systems (TCS) (Glaser et al., 2002; Tettelin et al., 2002; 
Tettelin et al., 2005), a number significantly grater than has been reported for 
closely related species such as GAS (13) or Lactococcus lactis (8) (Bolotin et al., 
2001; Ferretti et al., 2001). TCSs allow for the sensing of specific environmental 
stimuli or conditions followed by transduction of the signal to a response 
regulator. In the basic model, a membrane-bound histidine protein kinase 
(sensor) is autophosphorilated when the signal is detected. The phosphoryl group 
is then transferred to the cytoplasmatic response regulator. Phosphorilation of the 
regulator alters its binding affinity for the promoters of target genes, thereby 
affecting their transcription (Stoch et al., 2000).  The best characterized TCS in 
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GBS is the CsrS histidine kinase and CsrR response regulator pair, also known 
CsrRS (for capsule synthesis regulator, regulator and sensor components; also 
called CovRS). This TCS was originally identified by two separate groups, both of 
which demonstrated that it has global effects on gene expression that impact the 
virulence of GBS (Lamy et al., 2004; Jiang et al., 2005). The GBS CsrRS 
regulatory system is an ortholog of the GAS CovRS system that is known to be 
important for GAS virulence (Levin and Wessels, 1998; Federle et al., 1999). In 
GBS, csrS (sag1624) and csrR (sag1625) are components of a seven-gene 
operon that is not regulated by CsrR (Lamy et al., 2004). The function of other 
genes in the operon has not been fully elucidated. In a comprehensive analysis of 
this TCS, Lamy and colleagues reported that a csrRS deletion mutant displayed 
multiple phenotypic changes compared to the wild type strain, including increased 
hemolytic activity, reduced CAMP factor activity and increased adherence. The 
mutant was also unable to grow normally in human serum. Not surprisingly, the 
mutant was significantly attenuated for virulence in the neonatal rat sepsis 
infection model (Lamy et al., 2004).  The phenotypic changes that occurred in the 
csrRS mutant have been confirmed using microarrays to assess changes in gene 
expression. In GBS, the CsrRS TCS was shown to affect 140 genes during grown 
in vitro, with en equal numbers up-regulated and down-regulated. Many of 
affected genes encode proteins predicted to be secreted or localized to the cell 
surface. It is interesting that the target genes regulated by the CsrRS TCS in GBS 
and in GAS are not identical, despite the fact that the two systems are 
orthologous. The differences in target genes may be a reflection of the different 
host compartments encountered by these two pathogens.  
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Whereas the S. pyogenes system represses expression of all the major virulence 
factors it is known to control, Jiang and colleagues indicate evidence of both up- 
and down-regulation of different virulence determinants by GBS CsrRS. The GBS 
CsrRS system has divergent effects on different target genes or that it has 
regulatory activity on another regulator that, in turn, acts on one or more 
regulated structural genes. Interaction of the CsrRS system with other regulators 
could be part of a regulatory cascade or network in which multiple elements link 
an environmental stimulus with a series of downstream responses. The possibility 
of one or more intermediate regulators could explain the observed up (CAMP 
factor) and down (beta-hemolysin and C5a peptidase)-regulatory effects on 
different target genes (Jiang et al., 2005). 
CsrRS has a pivotal role in GBS phatogenesis of GBS infection; in fact 
transcriptional analysis showed that up to 7% of genes are under the control of 
this TCS (Jiang et al., 2008; Lamy et al., 2004). The genes regulated by CsrRS 
belong to differential functional categories, as cell envelope, cellular processes, 
metabolism, and virulence factor. Recently, it has been reported that CsrRS has 
an important role in the translocation of GBS from the acid pH of the vagina to the 
neutral pH of the newborn tissues, promoting a changing from a colonizing to an 
invasive phenotype (Santi et al., 2009). 
B. Carbon catabolite repression 
Carbon metabolism and its regulation are central to prokaryotic life. Sugars serve 
as the most facile source of carbon and energy, both of which are needed to 
replenish essential nucleotide cofactors and other metabolites in the cell. When 
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faced with a wide variety of carbon and energy sources, a bacterium has to make 
metabolic decisions, opting for preferential use of one source over another in 
order to maintain optimal growth (Deutscher, 2008; Stulke and Hillen, 1998; 
Titgemeyer and Hillen, 2002). Simultaneous utilization of all available sugars 
would be metabolically inefficient and would lead to slower growth. The ability to 
utilize preferred sugars depends on a regulatory process called carbon catabolite 
repression (CCR) (Stulke and Hillen, 1999; Titgemeyer and Hillen, 2002; Warner 
and Lolkema, 2003). CCR causes silencing of genes specific for the utilization of 
nonpreferred sugars until the bacterium has consumed the preferred sugar(s). 
CCR has been studied in considerable detail in the model free-living, Gram-
positive bacterium Bacillus subtilis (Stulke and Hillen, 2000; Titgemeyer and 
Hillen, 2002; Warner and Lolkema, 2003). The main global regulator of CCR in 
this organism is catabolite control protein A (CcpA) (Chauvaux, 1996; Henkin et 
al., 1991). CcpA belongs to the LacI/GalR family of activator-repressor 
transcription factors and influences the expression of a wide range of catabolic 
operons in B. subtilis (Belitsky et al., 2004; Grundy et al., 1994; Grundy et al., 
1993; Henkin, 1996; Hueck and Hillen 1995; Kim et al., 2002; Simpson and 
Russell, 1998; Stulke and Hillen, 2000; Warner et al., 2000; Warner and Lolkema, 
2003). CcpA has also been identified to function in the regulation of catabolic 
operons and catabolite repression in many streptococcal species (Iyer et al., 
2005; Asanuma et al., 2004, Dong et al., 2004, Rogers and Scannapieco, 2001, 
van den Bogaard et al., 2000). Candidate genes or operons that are subject to 
CcpA-dependent CCR are often identifiable by the presence of an operator 
sequence, called the catabolite-repressible element (cre), to which CcpA binds 
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(Asanuma et al., 2004; Kim and Chambliss, 1997; Miwa et al., 1997; Ramseier et 
al, 1995). In streptococcal species, several in vivo and in vitro studies have 
shown that the cre consensus sequence is WTGNAANCGNWNNCW (N is any 
base and W is A or T), where the underlined bases are involved in CcpA binding 
(Tomoyasu et al., 2010; Kim and Chambliss, 1997; Miwa et al., 2000; 
Schumacher et al., 2004; Warner and Lolkema. 2003).  
The affinity of CcpA for cre sequences is enhanced by binding to another protein, 
the histidine phosphoprotein (HPr). HPr is an integral component of the 
phosphoenolpyruvate-dependent phosphotransferase system (PTS), where it 
normally functions in the transfer of high-energy phosphate from 
phosphoenolpyruvate to the enzyme II complex during sugar uptake (Deutscher 
et al., 2006; Postma and Lengeler, 1985; Reizer et al., 1999). The presence of a 
preferred sugar, such as glucose, in the medium activates phosphorylation of HPr 
on a conserved serine residue at position 46 by the Hpr kinase, which itself is 
activated by metabolites such as the high-energy glycolytic intermediate fructose-
1,6-bisphosphate (Brochu and Vadeboncoeur, 1999; Frey et al., 2003; Poncet et 
al., 2004; Reizer et al., 1998; Thevenot, 1995). CcpA interacts with the 
phosphoserine form of HPr, P∼Ser-HPr, to form a dimeric complex. This 
interaction increases the affinity of CcpA for the cre box. Binding of this dimeric 
complex typically causes repression of promoters, facilitating CCR (Asanuma et 
al., 2004; Deutscher et al., 1995; Deutscher et al., 1994). CcpA residues involved 
in binding of P∼Ser-HPr (Kraus et al., 1998) and those involved in binding of cre 
(Kim and Chambliss, 1997) have been characterized, and the crystal structure of 
the CcpA-P∼Ser-HPr complex has been recently solved (Schumacher et al., 
2004). However, several reports have shown that although there is slightly low 
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affinity, CcpA can recognize and bind to the cre without HPr-(Ser- 46-P) and 
fructose-1,6-bisphosphate in vitro (Tomoyasu et al., 2010). 
2.5 Involvement of BibA and pullulanase in GBS pathogenesis 
Studies of the role of carbohydrate metabolism in streptococcal pathogenesis 
have focused on two mechanisms: adherence to eukaryotic cells and acquisition 
of crucial nutrients. Regulation of gene encoding for proteins involved in these 
pathways could be an important basis for understanding the molecular 
mechanisms underlying GBS pathogenesis. 
A. BibA: Group B Streptococcus immunogenic bacterial adhesin 
Recently, Santi and colleagues (Santi et al., 2007) have reported the presence of 
BibA, an immunogenic surface-associated antigen expressed by GBS that is 
involved in virulence. The protein product of the bibA (sag2063) gene in the GBS 
strain 2603 V/R (Tettelin et al., 2002) is a polypeptide of 630 amino acids 
containing a leader peptide (residues 1–27), a N-terminal domain (residues 28–
400), a proline rich region (residues 401–568) that consists of 42 copies of a 
PEAK/PDVK motif, and a canonical cell wall anchoring domain (residues 596–
630). The anchoring domain is formed by the consensus LPXTG sequence, 
followed by a hydrophobic transmembrane segment and a charged C-terminal 
tail.  As shown in ﬁgure 2.4, four allelic variants of this protein have been 
identiﬁed: variant I, found in strains 2603 V/R (V) and 18RS21 (II); variant II, in 
strains NEM316 (III) and 515 (Ia); variant III, in strains CJB111 (V), H36B (Ib), 
and A909 (Ia); and variant IV, in the COH1 (III) strain.  
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BibA is expressed on the surface of several GBS strains, but is also recovered in 
GBS culture supernatants. The two forms seem to have an identical MW and this 
suggests that secretion of BibA might be due to a proteolytic cleavage of the cell 
wall-anchoring domain (Santi et al., 2007). Exposure of BibA on the bacterial 
surface is correlated with protection, because mice immunized with BibA are 
protected against challenge by a GBS strain with high levels of surface exposure 
of the antigen. Furthermore, serum samples from mice immunized with 
recombinant BibA induced neutrophil-mediated in vitro opsonophagocytic killing 
of GBS (Santi et al., 2009b). 
Deletion of the bibA gene severely reduced the capability of GBS to survive in 
human blood and to resist opsonophagocytic killing by human neutrophils. bibA 
knockout mutant strain of GBS shows an impaired capability to adhere to both 
Figure 2.4 Overview of sequence organization in BibA proteins. 
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human cervical and lung epithelial cells, demonstrating the effective role of BibA 
as adhesin (Santi et al., 2007). 
The presence of this protein on GBS surface is influenced by various 
environmental factors (Mereghetti et al., 2008; Santi et al., 2009a). GBS adapts to 
different environmental conditions by modulating the transcription of genes 
involved in pathogen-host interaction (Boskey et al., 1999). An important 
condition that affects the gene expression is the pH; in the human host, GBS 
encounters pH conditions that vary from the acidic pH of the vagina or 
intracellular endocytic compartments to the near-neutral pH of amniotic ﬂuid or 
the fetal. Moreover, a comparative global gene expression analysis of GBS grown 
at acidic and neutral pHs has shown a down regulation of bibA expression when 
GBS is grown at acidic pH compare to a grown at pH 7 (Santi et al., 2009a). 
Furthermore, the regulation of the gene is under the control of two component 
system CsrRS, in fact the expression level of bibA doesn’t change in the csrRS 
deletion mutant strain grown in both conditions, meaning that the signal is 
transducted by these regulatory components.  
B. Pullulanase 
The use of carbon sources is essential to the ability of bacteria to colonize the 
host and potentially cause disease in humans. In particular, highly polymerized α-
glucan polysaccharides, such as starch and glycogen, are most likely to be found 
in environmental niches. Indeed, it is known that dietary-derived starches are very 
abundant in the human colon (Anderson et al., 1981; Levitt et al., 1987), while 
glycogen is deposited in large amount in the vaginal ephitelium during times of 
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high estrogen availability. Because of the complex structures of highly 
polymerized α-glucans, bacteria require an appropriate combination of enzymes 
for de-polymerization to oligo- and monosaccharides. Among these enzymes are 
ascribed pullulanases. Pullulanases have a glycosidic hydrolase activity towards 
α-glucan polysaccharides and are considered key extracellular components in 
bacterial metabolism. 
Recently it is identified in GBS a novel surface-exposed α-glucan-degrading 
enzyme, named SAP (Streptococcus agalactiae pullulanase), belonging to the 
streptococcal family of pullulanases (Santi et al., 2008). The sap gene (sag1216) 
is highly conserved among Group B streptococcus (GBS) strains; homologous 
genes, such as those for pulA and spuA, are present in other pathogenic 
streptococci. SAP is a member of the class 13 glycoside hydrolase (GH13; α-
amylase) family and is a type I pullulanase; in vitro studies have shown that 
recombinant SAP can degrade α-glucans such as pullulan, glycogen, and starch 
(Santi et al., 2008). Furthermore, fluorescence-activated scanning analysis and 
confocal imaging studies performed on whole bacteria indicate that the presence 
of α-glucan polysaccharides in culture medium upregulates the expression of 
SAP on the bacterial surface (Santi et al., 2008). As reported for other 
streptococcal pullulanases, specific anti-SAP antibodies are found in human sera 
from healthy volunteers. Investigation of the functional role of anti-SAP antibodies 
revealed that incubation of GBS in the presence of sera from animals immunized 
with SAP reduced the ability of the bacterium to degrade pullulan.  
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3. Material and methods 
3.1 Bacterial strains and growth conditions 
GBS type V strain 2603V/R and isogenic mutant strain 2603ΔcsrRS have been 
described previously (Tettelin et al., 2002; Jiang et al., 2005). E. coli DH10BT1 
and HK100 strains were used for cloning purposes. E. coli BL21 (DE3) strain was 
used for protein production. Unless otherwise specified, for experiments testing 
the effects of glucose, GBS was cultured at 37°C in Todd-Hewitt broth (Difco) and 
in a sugar-free complex medium (CM: 10 g/l proteose peptone, 5 g/l trypticase 
peptone, 5 g/l yeast extract, 2.5 g/l KCl, 1 mM urea, 1 mM arginine). E. coli was 
grown in Luria–Bertani broth and ampicillin was used at a final concentration of 
100 μg/ml for recombinant strains. 
3.2 Microarray analysis of gene expression 
Microarray comparison was performed on the wild-type strain 2603 V/R and the 
isogenic mutant strain 2603 csrRS.  
The two strains were grown in THB until late exponential phase, washed in PBS 
and resuspended in CM until OD600 of 0.5. The bacteria were washed in PBS and 
resuspendend in CM in the absence or presence of 1% glucose at 37°C for 30 
minutes of incubation. Total RNA was extracted with RNeasy Mini Kit (Qiagen) 
and treated with RNase-free DNase (Qiagen) according to the manufacturer's 
instructions. The concentration of total RNA was determined using a NanoDrop 
ND-1000 spectrophotometer (NanoDrop Technologies). RNA integrity was 
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verified using a Bioanalyzer 1000 (Agilent). For each strain, total bacterial RNA 
was isolated from four independent culture pools and the samples were sent to 
Roche NimbleGen Systems, where cDNA synthesis and labeling were performed. 
Changes in gene expression levels were evaluated using the NimbleGen GBS 
DNA microarray (17 probes for each gene, 3 replicates for probe consisting of 60-
mer synthetic oligonucleotides for each gene). All hybridizations, staining, and 
processing were performed by personnel at Roche NimbleGen, Inc. (Madison, 
WI, USA). 
Briefly, to synthesize double-stranded cDNA, 10 ug of RNA were retrotranscripted 
using the Invitrogen SuperScript Double-Stranded cDNA Synthesis Kit. To 
eliminate RNA contaminations, a step with RNase was performed. The cDNA was 
precipitated with phenol:chloroform:isoamyl alcohol and quality control was 
analyzed using a spectrophotometer. The cDNA was labeled using the 
NimbleGen One-Color DNA Labeling Kits (labeling with Cy3). 
Equal amounts of cDNA was then hybridized onto the Slide 12x135K (Design 
Name: 100920_TI208435_60mer_HX12) for Streptococcus agalactiae, using the 
NimbleGen Hybridization System and according to protocol "NimbleGen Arrays 
User’s Guide, Gene Expression Arrays, Version 5.1" (NimbleGen Roche). cDNA 
were hybridized onto microarray at +42°C  for 16 hours. After hybridization, 
microarray was disassembled, washed following the NimbleGen's protocol. The 
slides were dried in NimbleGen Microarray Dryer (NimbleGen Roche) for 2 
minutes and immediately scanned with the MS 200 Microarray Scanner 
(NimbleGen Roche) following the protocol. Scanned image and data were 
extracted and analyzed using NimbleScan software. NimbleScan software 
normalizes expression data using quantile normalization as described by Bolstad, 
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(Bolstad et al., 2003). Gene calls are generated using the Robust Multichip 
Average (RMA) algorithm as described by Irizarry (Irizarry et al., 2003a; Irizarry et 
al., 2003b). 
The raw data were analyzed using the DNASTAR software.  
The microarray experiment has been submitted to the Array Express database of 
the European Bioinformatic Institute (http://www.ebi.ac.uk/microarray-as/ae/) with 
accession number A-MEXP-2195 (Chip design). 
3.3 Quantitative reverse transcriptase PCR 
Quantitative real-time PCR (qRT-PCR) was used to validate microarray 
experiments. One microgram of RNA previously extracted for microarray was 
incubated with random primers and used for cDNA synthesis (at 42°C, one hour 
incubation) using ImProm-II Reverse Transcriptase (Promega). Fifteen microliters 
of cDNA were used as template for PCR amplification using gene specific primers 
as listed in Table 3.1. The amplification was performed using FastStart Universal 
SYBR Green Master (Rox) (Roche), employing Light Cycler 480 System (Roche). 
The expression levels of all the genes tested by quantitative RT-PCR were 
normalized using the gyrA expression as an internal standard. Each sample was 
tested in triplicate during a trial, and three independent experiments were 
performed. 
3.4 Flow cytometry analysis 
To verify the exposure of BibA on bacterial surface, GBS was incubated for 30 
minutes in CM in the absence or presence of 1% glucose employing the same 
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conditions used for microarray experiments. After the grown, the bacteria were 
washed twice with PBS, suspended in newborn calf serum (Sigma), incubated for 
20 min at room temperature, and dispensed in a 96-well plate (20 μl per well). 
The bacteria were fixed in 1% paraformaldehyde for 15 minutes at room 
temperature. Eighty microliters of anti-BibA immune rabbit serum diluted in 
PBS/0.1% BSA was added to the bacterial suspension to a final dilution of 1:200. 
Incubation was performed at 4°C for 1 hour. After washing, bacteria were labeled 
with R-Phycoerythrin (PE)-conjugated secondary antibodies (final dilution 1:100) 
(Jackson Immuno Research, PA, USA) at 4°C. Pre immune serum from rabbit 
was used as a negative control. Bacterial staining was analyzed by using a FACS 
CANTO II Flow cytometer equipped with three laser system (405, 488, 633 nm), 
eight Color Configuration and BD FACSDivaTM v6.1.3 software (BD Bioscience, 
SANJOSE, CA) and the data were analyzed with FlowJo 7.2.2 program. 
3.5 SDS-PAGE and Immunoblot analysis 
In order to prepare GBS extracts relative to the secreted protein fraction, 
supernatant of bacteria cultures grown in the same conditions used for microarray 
were collected. Proteins in 1 ml of supernatant were precipitated with 10% of 
trichloroaceticacid (TCA) for 1 hr at 4°C. Protein were then pelletted, washed with 
cold acetone and resuspended in Tris-HCl pH 6,8. Bacterial proteins were 
separated by 4-12% SDS-polyacrylamide gel electrophoresis (SDS-PAGE) (Bio-
Rad) and transferred to nitrocellulose membranes (Bio-Rad). Membranes were 
blocked with milk (5% w/v) and, then, incubated with anti-BibA immune rabbit 
serum at a 1:1000 dilution, secondary antibody (ECL, horseradish peroxidase-
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linked anti-mouse IgG, GE Healthcare) at a 1:1000 dilution and developed with 
ECL enhanced chemiluminescence detection substrate (SuperSignal West Pico, 
Pierce). 
3.6 Cloning, production and purification of recombinant 
proteins CsrR 
The csrR gene (sag1625) was amplified by PCR from GBS genome using the 
primers (Fw csrR, Rv csrR) listed in Table 3.1, carrying the cleavage sites of the 
restriction enzyme NdeI and XhoI at 5’ end. The PCR product was digested with 
the specific restriction enzymes and cloned into pET 21b (Novagen) previously 
linearized with the same restriction enzymes. The construct was introduced into 
BL21 (DE3) by transformation. 
The recombinant bacteria were grown at 37°C to an optical density at 600 nm of 
0.5 (mid exponential phase), at which time 1mM isopropyl-beta-D-
thiogalactopyranoside (IPTG) was added. After 3 hours, the cells were harvested 
by centrifugation, resuspended in buffer A (50 mM Na2HPO4 [pH 8], 0.3 M NaCl) 
and distrupted by sonication (10 cycles, 30 sec ON 30 sec OFF). The purification 
on the soluble fraction was performed with His Gravi Trap columns (GE 
Healthcare): the lysate was loaded onto the columns and after several washing in 
buffer B (50 mM Na2HPO4 [pH 8], 0.3 M NaCl, 20 mM imidazole) the recombinant 
proteins were eluted with high concentration imidazole buffer (50 mM Na2HPO4 
[pH 8], 0.3 M NaCl, 250 mM imidazole). Protein concentration was estimated 
using the Bradford assay (Bradford, M. M. 1976), and protein content was 
checked by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
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PAGE). After the purification, the protein was dialyzed against buffer A to remove 
the imidazole content. 
3.7 Electrophoretic mobility shift assays on bibA promoter 
Elecrophoretic mobility shift assays were performed in order to verify the binding 
of CsrR to the bibA promoter. Biotin-labeled primers (Fw bibA, Rv bibA, Table 
3.1) were used to amplify DNA fragments corresponding to the promoter region of 
bibA (sag2063). As unrelated sequence, sag0017 promoter was amplified by 
PCR using the biotin-labeled primers (Fw sag0017, Rv sag0017, Table 3.1). 
Various amounts of purified recombinant CsrRS (phosphorylated and not 
phosphorylated) were incubated with 1 ng of labeled probes in 20 µl of buffer Z 
(25 mM HEPES, pH 7.6, 50 mM KCl, 12.5 mM MgCl2, 1 mM dithiothreitol [DTT], 
20% glycerol, 0.1% triton) for 20 minutes at room temperature. The reactions 
were stopped with 2 µl of 50% glycerol and the protein-DNA complexes were 
separated on native 6% polyacrylamide gels in 0.5X TBE (45 mM Tris, pH 8.0, 45 
mM boric acid, 1 mM EDTA) at 100 V (20 V/cm) at room temperature. Afterwards, 
electrophoretic transfer to a nylon membrane (GE Healthcare) was performed in 
0.5X TBE at 380 mA for 45 minutes, and the transferred DNA was cross-linked to 
the membrane with UV light. After incubation in blocking buffer (2% milk in PBS 
with 0.5% Triton [PBS-T]) for 1 hour at room temperature, the membrane was 
incubated with streptavidin-horseradish peroxidase (HRP) conjugate (Pierce) for 
1 hour at room temperature at a final dilution 1:1000. The membrane was washed 
and visualized with SuperSignal chemiluminescence reagent (Pierce). EMSAs 
were also performed using  phosphorylated His-tagged CsrRS: the in vitro 
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modification was obtained incubating 10 µg of protein with 32 mM acetyl 
phosphate in freshly made phosphorylation buffer (20 mM NaH2PO4, [pH 8.0], 10 
mM MgCl2, 1 mM DTT) in a total volume of 100 µl for 90 minutes at room 
temperature (Jiang et al., 2004). 
The specificity of CsrR binding to the bibA promoter was tested by competition 
EMSA performed using increasing quantities (250x-500x) of either unlabelled 
bibA promoter (used a specific competitor) or sag0017 promoter (used as a non 
specific competitor). 
3.8 Chromatin immunoprecipitation 
The transcriptional role of CsrR in bibA gene regulation was investigated in vivo 
by ChIP. GBS wild type strain and isogenic mutant strain 2603ΔcsrS grown in CM 
in presence or not of glucose were fixed with 1% formaldehyde at room 
temperature for 15 minutes under gentle agitation and cross linking reaction was 
stopped by the addition of glicyne (0.125 M) for 10 minutes. Bacteria were 
harvested by centrifugation, washed twice in 1 volume of cold phosphate-buffered 
saline, washed once in 150 mM NaCl, 10 mM Tris-HCl (pH 8.0), 10 mM EDTA 
(pH 8.0), and 0.25% Triton X-100, and resuspended in 2 ml TE (10 mM Tris-HCl 
[pH 8.0], 1 mM EDTA). The samples were sonicated in ice and the average size 
of sheared DNA was determined to be ∼0.5 kb. Cell debris was removed by 
centrifugation and the supernatant was used as the chromatin input for the 
immunoprecipitation reactions, after an initial stage of pre-clearing with 100 µl 
50% protein A-Sepharose slurry (Pharmacia) for 45 minutes at 4°C. Precleared 
cell extracts (0.9 ml) were incubated overnight with 10 µl CsrR antiserum in 1x 
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radioimmunoprecipitation assay (RIPA) buffer (140 mM NaCl, 10 mM Tris-HCl 
[pH 8.0], 1 mM EDTA, 1% Triton X-100, 0.1% SDS, 0.1% Na deoxycholate) at 
4°C, and CsrR-DNA complexes were immunoprecipitated with 50 µl 50% protein 
A slurry (preequilibrated in 1x RIPA buffer) for 3 hours at 4°C in sterile disposable 
minicolumns (Bio-Rad). After four washing steps in RIPA buffer, one in LiCl buffer 
(250 mM LiCl, 10 mM Tris-HCl [pH 8.0], 1 mM EDTA, 0.5% NP-40 [Igepal], 0.5% 
Na deoxycholate), and twice in TE, the immuno-complex was resuspended in 100 
µl TE. Treatment for 30 minutes at 37°C with RNase A (20 µg/ml) and overnight 
digestion with 50 µg/ml proteinase K in 0.5% SDS at 37°C were performed to 
recover DNA. Cross-linking was reversed for 6 hours at 65 °C and DNA was 
extract with organic solvents and resuspended in 100 µl of distillated water. The 
presence of the target promoter sequences in the chromatin immunoprecipitates 
was detected by DotBlot analysis (Danielli et al., 2006) 
3.9 Cloning, expression and purification of recombinant 
proteins CcpA 
The ccpA gene (sag0707) was cloned into the pET-15 vector (Novagen) using the 
Polymerase Incomplete Primer Extension (PIPE) methodology described by 
Klock and Lesley (2009). The primers Fw ccpA, Rv ccpA, Fw pET-15, Rv pET-15 
are listened in Table 3.1. PCR product and vector were directly transformed into 
E.coli HK100 recipient cells. Single ampicillin resistant colonies were selected 
and checked for the presence of recombinant plasmid by colony PCR. Competent 
E.coli BL21 (DE3) cells were transformed with the plasmids purified from positive 
clones. 
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The recombinant bacteria were grown at 37°C to an optical density at 600 nm of 
0.5 (mid exponential phase), at which time 1mM isopropyl-beta-D-
thiogalactopyranoside (IPTG) was added. After 3 hours, the cells were harvested 
by centrifugation, resuspended in buffer A (50 mM Na2HPO4 [pH 8], 0.3 M NaCl) 
and distrupted by sonication (10 cycles, 30 sec ON 30 sec OFF). The purification 
on the soluble fraction was performed with His Gravi Trap columns (GE 
Healthcare): the lysate was loaded onto the columns and after several washing in 
buffer B (50 mM Na2HPO4 [pH 8], 0.3 M NaCl, 20 mM imidazole) the recombinant 
proteins were eluted with high concentration imidazole buffer (50 mM Na2HPO4 
[pH 8], 0.3 M NaCl, 250 mM imidazole). Protein concentration was estimated 
using the Bradford assay (Bradford, M. M. 1976), and protein content was 
checked by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE). After the purification, the protein was dialyzed against buffer A to remove 
the imidazole content. 
3.10 Electrophoretic mobility shift assays on sap promoter 
Elecrophoretic mobility shift assays were performed in order to verify the 
interaction of CcpA with the sap promoter. A biotin labeled Fw sap and Rv sap 
primers were used to amplify the promoter by PCR; as negative control of the 
experiment, bibA promoter used in previous EMSA was employed. 25 ng of both 
DNA were incubated with the recombinant protein in 20 µl of buffer Z (25 mM 
HEPES, pH 7.6, 50 mM KCl, 12.5 mM MgCl2, 1 mM dithiothreitol [DTT], 20% 
glycerol, 0.1% triton) for 20 minutes at room temperature. The DNA-protein 
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complexes were separated on 1% agarose gel, run in 1X TAE (40 mM Tris-
acetate, 1mM EDTA) at 100 V (20 V/cm) at room temperature. 
To better define the binding site for CcpA on sap promoter, EMSA probes were 
prepared by annealing biotin-labeled forward and reverse oligonucleotides (Fw 
cre box, Rv cre box, Fw mutated cre, Rv mutated cre, Table 3.1) by incubation at 
95°C for 5 min and successive gradual cooling to room temperature. Various 
amounts of purified recombinant CcpA were incubated with 1 ng of labeled 
probes in 20 µl of buffer Z for 20 minutes at room temperature. The reactions 
were stopped with 2 µl of 50% glycerol and the protein-DNA complexes were 
separated on native 6% polyacrylamide gels in 0.5X TBE (45 mM Tris, pH 8.0, 45 
mM boric acid, 1 mM EDTA) at 100 V (20 V/cm) at room temperature. Afterwards, 
electrophoretic transfer to a nylon membrane (GE Healthcare) was performed in 
0.5X TBE at 380 mA for 45 minutes, and the transferred DNA was cross-linked to 
the membrane with UV light. After incubation in blocking buffer (2% milk in PBS 
with 0.5% Triton [PBS-T]) for 1 hour at room temperature, the membrane was 
incubated with streptavidin-horseradish peroxidase (HRP) conjugate (Pierce) for 
1 hour at room temperature at a final dilution 1:1000. The membrane was washed 
and visualized with SuperSignal chemiluminescence reagent (Pierce).  The 
specificity of CcpA binding to the cre sequence was tested by competition EMSA 
performed using increasing quantities (100x-500x) of either unlabelled cre box 
(used a specific competitor) or mutated cre (used as a non specific competitor). 
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Table 3.1 Primers used for this work 
Primer                           Sequence (5’-3’) 
Fw RT gyrA CTTGACGAAGGTGAGACAATTC 
Rv RT gyrA TTGAAGCGAACAGAGTAGCC 
Fw RT cfb TTAAGGCTTCTACACGACTACC 
Rv RT cfb CAAGTGACAACTCCACAAGTG 
Fw RT bibA TGCCTACACCTGGATATTATGC 
Rv RT bibA GGCTTAGCTTCTGGTTTAACG 
Fw RT cylX CTGAGTTTCTTACGGAAGGTGGTG 
Rv RT cylX ATCAACGACACTGCCATCAGCACA 
Fw RT potB ACACCTGCTCTTACACCATTC 
Rv RT potB GGGAATTAACGCCTTCTTAACC 
Fw RT sag1333 AGGCGTCAATGACTTTCATGGTGC 
Rv RT sag1333 ACCATATCGCCTGCTTGAACCCTA 
Fw RT sag2021 CCACATGGTTCTAGTGGAAGCGTT  
Rv RT sag2021 TTTCTGTTGACGGTGGTGTTGGCT 
Fw RT sag0677 GTTTGCAGTTGCTGGACCACAAGA  
Rv RT sag0677 GAGTTGCCTCACTAGCAGTTTCCA 
Fw RT sap  TGATGCGGCTGCGATTGAATTAGC 
Rv RT sap ATGTTCTCCAGCCCTCACCAATCA 
Fw csrR GGAATTCCATATGGGTAAAAAGATCTTAATAATCGAAG 
Rv csrR CCCGCTCGAGTTTTTCACGAATCACATAGCCCATT 
Fw bibA ATAATAGATTATTTTAGATAGAAACAACCC 
Rv bibA CATATTCGCTCCTTTATATAGTTAGTTG 
Fw sag0017 GAGGACGGTTTGCTAAATCGTTAGG 
Rv sag0017 TTCATTTTTATTAAACTACTCCTTTACGAT 
Fw ccpA CTGTACTTCCAGGGCATGAATACAGATGATACGATTACGATTTA 
Rv ccpA AATTAAGTCGCGTTACTAATTATTTGTTGTGCCACGTTTAACAA 
Fw pET-15 TAACGGACTTAATTAACGGTCTCCAGCTTGGCTGTTTTGGC 
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Rv pET-15 GCCCTGGAAGTACAGGTTTTCGTGATGATGATGATGATG 
Fw sap  AGGAAATTTTTGATAAAAAAGCTAGGCAATATT 
Rv sap TATCATTCTCCTTTTTTAATGAATTGTTACC 
Fw cre box  TTACTTGTTGCAAGCGCTTGCGTAAATTG 
Rv cre box CAATTTACGCAAGCGCTTGCAACAAGTAA 
Fw mutated cre TTACTTGTATCGTTAAAGCTAGTAAATTG 
Rv mutated cre CAATTTACTAGCTTTAACGATACAAGTAA 
 
  
  
  
  
  
38 
 
4. RESULTS 
4.1 Regulation of GBS gene expression by glucose  
To elucidate the response of GBS to glucose stress conditions, we performed a 
comparative global gene expression analysis of the 2603 V/R GBS strain grown 
at mid-exponential phase in a pepton-based complex medium (CM) devoid of 
sugars versus bacteria incubated for 30 min in CM containing 1% glucose. We 
found that, in such conditions, 27.5% of the genes were differentially expressed, 
with 353 of them up-regulated and 225 down-regulated. As expected, among the 
most regulated functional families, we found genes related to energy metabolism. 
Genes encoding transport and binding proteins were also highly regulated (Fig. 
4.1). Of importance, a number of virulence genes were modulates by glucose, 
indicating a role in the adaptation of GBS to stress conditions. The microarray 
data were validated by real-time RT-PCR on eight genes, using total RNA 
isolated from wild-type and csrRS knockout strains grown in the presence or 
absence of glucose (see Table 4.1). The changes in response to glucose stress 
conditions observed in wild-type GBS and in the mutant strain were very similar to 
those measured by global gene expression analysis. 
A list of the most regulated genes at high glucose conditions is reported in Table 
4.2. 
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4.2 Functional categories 
A. Stress response of GBS in high glucose condition 
Growth in high glucose medium involves a considerable change in expression of 
genes involved in adaptation and stress response. Among stress response 
genes, a dramatic change was observed in the transcript for sag1677, encoding a 
universal stress protein, whose expression was highly down-regulated (27-fold) 
following exposure to glucose. Several genes, including sag1135, sag1136, 
sag1137, encoding stress proteins were down-regulated, too. Interestingly, these 
stress proteins are homologs of Gls24, a general stress protein of Enterococcus 
faecalis which has been reported to have a crucial role in stress response as well 
as in virulence (Teng et al., 2004). 
B. Transcriptional regulators 
After 30 minutes of incubation with 1% glucose several transcriptional regulators 
were modulated. In particular, sag1128, sag2017, sag0554 belonging to the 
putative Cro/CI family and sag1749, sag1655, sag0427, being part of the putative 
Mer family of regulators, were 2-5 fold up-regulated. Of interest, the latter family 
has been reported to act as a key activator in nitric oxide defense system in 
pneumococci, thus ensuring both survival and systemic infection (Stroeher et al., 
2007; Brown et al., 2003) 
In response to the availability of glucose sources, bacteria inhibit multiple 
enzymes responsible for alternative sugar metabolism pathways through the 
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carbon catabolite repression system (CCR), mediated by the catabolite control 
protein A (CcpA, sag0707). Bioinformatic analysis revealed that a number of 
transcriptional regulators, that were highly down-regulated under glucose 
conditions (up to 20-fold), has in their promoter region a consensus sequence for 
the binding of CcpA 
(http://regprecise.lbl.gov/RegPrecise/gmregulon.jsp?gmproject_id=6875). They 
included: sag0277, encoding a Mga-like protein, a positive regulator of virulence 
in GAS (Almengor et al., 2007; sag1348, fruR, lactose phosphotrasferase system 
repressor; sag0119, rbsR, ribose operon repressor; sag0042, phosphosugar-
binding transcriptional regulator belonging to RpiR family; sag2073, a 
transcriptional regulator belonging to GntR family; sag2161, encoding for a 
transcriptional regulator of the Crp/Fnr family and CcpA itself.  
C. Transport genes 
Several genes encoding transport proteins were found to be up-regulated in high 
glucose conditions. These included sag0745, coding for a putative transporter of 
the NRAMP family, involved both in Mn2+ and Fe2+ uptake (Janulczyk et al., 2003; 
Papp-Wallace and Maguire, 2006) and genes encoding for proteins involved in 
potassium uptake, such as sag1590, sag1591, sag1631 (belonging to the trk 
family) and sag1090. We also observed a five fold upregulation of the sag1711 
gene, coding for a putative CorA protein involved in magnesium transport 
(Warren et al., 2004).  A number of genes belonging to the transport family and 
found to be up-regulated by glucose are interestingly involved in peptide uptake, 
a process essential to satisfy GBS growth requirement, given that this bacterium 
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has a limited capacity to synthesize amino acid. Among up-regulated genes, 
although regulated at different extent, we found the dps gene (sag1444), coding 
for a putative peptide/proton symporter (Samen et al., 2004); a putative histidine 
ABC transporter (sag0947 to sag0949);  a spermidine-putrescine transporter, 
potABCD (sag1108 to sag1111), implicated in the pathogenesis of Streptococcus 
pneumoniae in various infection models (Shah et al., 2011); the sag0290 to 
sag0292 operon (regulated up to 8-fold), encoding a putative polar amino acid 
ABC transporter; the sag1145 gene, encoding for the sodium:alanin symporter 
protein; the sag0715 to sag0718 and sag0947 to sag0949 genes, all encoding for 
amino acid ABC transporters. Furthermore, we found up-regulated the region 
comprising the sag0241 to sag0244 genes, encoding an ABC transporter for 
glycine betaine, whose accumulation in B.subtilis and L.lactis confers protection 
against osmotic and cold stress to the bacterium (Hoffmann et al., 2002; 
Hoffmann and Bremer, 2011; Obis et al., 1999). 
As expected, in high glucose condition genes involved in the transport of complex 
carbohydrates were also down-regulated, including the region from sag1441 to 
sag1443, encoding for the maltose-maltodextrin transport system (malE-F-G); 
sag0955 and sag1925 (msmK) genes, encoding a sugar-ABC transporter and a 
sugar transport ATP-binding protein, respectively; the ribose ABC transporter 
region (from sag0114 to sag0117, namely rbsA-B-C-D); the cellobiose ABC 
transporter (sag0328 to sag0330). Furthermore several multiple transport 
systems (PTS), which allow uptake of various carboydrate sources, such as 
sag1805, sag1813, sag1814, sag1948-1951, sag1898-1902 and sag0192, 
showing a specificity for different sugars, were found to be highly down-regulated 
(up to 120-fold). 
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D. Wide-ranging changes in GBS adaptive metabolism 
The expression of several genes involved in a wide range of metabolic pathway 
was dramatically modulated by a 30 minutes incubation in 1% glucose, mirroring 
a rapid adaptation of GBS cellular process metabolism to conditions and nutrients 
in the new environment. We observed that bacteria grown in such a rich medium 
were growing more rapidly, thus, as expected, gene encoding for DNA replication, 
recombination and repair and gene encoding for membrane biosynthesis were 
found to be highly up-regulated, while genes encoding for enzymes involved in 
substrate degradation were found to be down-regulated. Transcript changes were 
observed in  aminoacid classes, in particular the sag2165 and sag2167, which 
encode for a carbamate kinase and an ornithine carbamoyltransferase, 
respectively, were highly down-regulated (up to 20-fold). Both enzymes are 
components of the arginine deaminase system, which has been suggested to aid 
bacterial survival in acidic environments by catalyzing the release of ammonia 
from arginine (Gruening et al., 2006). The sag1907 gene (eda-2), encoding for 
keto-hydroxyglutarate-aldolase/keto-deoxy-phosphogluconate aldolase, was 
found to be highly down-regulated, too. Conversely few genes were slightly up-
regulated, such as genes belonging to the aspartate and serine families.  
We found a drastic down-regulation (up to 130-fold) of genes implicated in energy 
metabolism of sugars, including the sag0033 to sag0042 locus, encoding for the 
sialic acid operon. The list also comprises a carbohydrate kinase (sag1906) 
belonging to PfkB family; a putative hexulose-6-phosphate synthase (sag1812); 
L-a ribulose-5-phosphate 4-epimerase (sag1810); a putative hexulose-6-
phosphate isomerase (sag1811); and the sag0118 gene encoding for a 
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ribokinase. Also genes encoding for proteins required for fermentation processes 
were found to be down-regulated, including sag1637, sag0053 and sag0054, 
annotated as alcohol dehydrogenases (adh, adhP, adhE). The repression of 
genes codifying for proteins implicated in biosynthesis and degradation of 
polysaccharides such as sag1901, glucuronyl hydrolase; sag0041, acetyl xylan 
esterase; sag1216, pullulanase; sag0856,  glycogen synthase (glgA); sag0854, 
glucose-1-phosphate adenylyltransferase (glgC); sag0853 glycogen branching 
enzyme (glgB) was also observed.  
E. Virulence and host-pathogen interaction genes 
Pathogenic bacteria by modulating the expression of surface-associated or 
secreted virulence factors can adapt to host conditions and improve their capacity 
to persist in specific niches. Although pathologic high glucose conditions are often 
associated to an increased risk for GBS infections, we found that transcription of 
known or putative virulence factors was down-regulated in response to glucose 
stress conditions, indicating that in this particular scenario such determinants may 
be dispensable to GBS invasiveness. In particular the expression of pore-forming 
toxins including a) the cyl gene cluster (sag0662 to sag0673), required for GBS 
hemolysin production, which is responsible for promoting invasion of host cells 
and triggering cell lysis (Pritzlaff et al., 2001) ,and b) the cfb gene (sag2043), 
encoding the CAMP factor (Lang and Palmer, 2003), was down-regulated in a 
range between 6 to12 fold. 
A similar pattern of expression was observed for several surface-expressed 
proteins containing the LPXTG cell wall-sorting motif, such as bibA (sag2063). 
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Among virulence factors involved in host cell adherence and invasion, the 
expression of the sag1234 gene encoding for the laminin binding protein, Lmb, 
which promotes adherence of GBS to host cells by binding to ECM laminin 
(Spellerberg et al., 1999), was repressed by glucose. Furthermore, we found that 
also the expression of sodA (sag0788), a gene which plays a crucial role against 
oxidative stress (Poyart et al., 2001), and of the hyaluronate lysase (sag1197), 
which cleaves hyaluronic acid, a major component of the connective tissue, thus 
promoting GBS spreading during infection, was significantly reduced. 
On the contrary only few genes were found to be up-regulated, such as sag0677, 
encoding an unknown function LPXTG protein, and sag2021, encoding for a 
protein binding to human glycoprotein GP-340 thus preventing bacterial 
colonization (Brady et al., 2010). The same activation trend was observed for the 
sag1739 to sag1744 operon, encoding proteins which although not officially 
classified among virulence factors, have been reported to be involved in the 
respiration metabolism and to play a role in virulence and GBS growth in vivo 
(Yamamoto et al., 2005). 
4.3 The response to glucose involves the two component 
system CsrRS  
By comparing previously reported information on genes controlled by the CsrRS 
two-component system (Lamy  et al., 2004) and the array of genes modulated by 
glucose, we found a number of common genes, including sag0662 to sag0673 
(cyl operon), sag2043 (cfb) and sag2063 (bibA). Therefore to  postulate whether 
glucose-dependent regulation of gene expression was under the control of CsrRS 
45 
 
system, we carried out transcriptome analysis of an isogenic ΔcsrRS mutant 
strain grown under glucose rich conditions and compared it to an isogenic wild 
type strain grown at the same conditions. Of importance, a large number of 
glucose-dependent genes (~36%), mainly factors implicated in GBS transposon 
function and virulence, resulted to be under CsrRS regulation (Fig. 4.2). 
 
Table 4.1 Real time PCR confirmed the results of microarray experiments. 
 
           2603 V/R                 ΔcsrRS 
 
microarray real-time microarray real-time 
potB 2,0up 2,1 up  1,8 up 3,3 up 
bibA 2,4 down 2,1 down 1,5 down 1,4 down 
cfb 5,8 down 7,8 down 3,7 down 3,3 down 
cylX 9,0 down 11,8 down 2,4 down 4,6 down 
sap 20,6 down 39,3 down 74,7 down 129,2 down 
sag1333 3,3 down 3,9 down 1,6 down 1,5 down 
sag2021 3,8 up 2,1 up 1,9 up 1,2 up 
sag0677 2,9 up 1,3 up 1,1 down 1,2 up 
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Table 4.2 List of genes highly regulated in GBS strain 2603V/R after incubation in high glucose 
medium. 
TIGR 
locus 
Annotation Family Fold 
change 
Regulation 
sag0008        Transcription-repair 
coupling factor (mfd) 
DNA metabolism             6.1 Up 
sag0185                  Hypothetical protein Cell envelope                10.24 Down 
sag0281        Hypothetical protein Cell envelope                                  7.04 Down 
sag2169                           Hypothetical protein Cell envelope               8.35 Up 
sag0040        ROK family protein Unknown function                        48.35 Down 
sag1643        Glutamine 
amidotransferase, class I 
Unknown function                        19.91 Up 
sag0034                              Sugar ABC transporter Transport and binding 
proteins   
128.03 Down 
sag1949                                                          PTS system Transport and binding 
proteins    
84.29 Down 
sag1950 PTS system Transport and binding 
proteins    
119.63 Down 
sag1951 PTS system Transport and binding 
proteins    
92.69 Down 
sag1642                 ABC transporter Transport and binding 
proteins      
19.12 Up 
sag0664                                                                          CylG protein (cylG) Cellular processes                          12.25 Down 
sag0663                                                                                 CylD protein (cylD) Cellular processes                          11.63 Down 
sag0667                                                                                CylA protein (cylA) Cellular processes                          10.16 Down 
sag0666        CylZ protein (cylZ) Cellular processes                             9.92 Down 
sag0662                      CylX protein (cylX) Cellular processes                            8.99 Down 
sag0668                                                                   CylB protein (cylB) Cellular processes                            8.82 Down 
sag0669                     CylE protein (cylE) Cellular processes                            8.79 Down 
sag0670                                                                            CylF protein (cylF) Cellular processes                           8.63 Down 
sag0671                                                                               CylJ protein (cylJ) Cellular processes                           7.01 Down 
sag0672                                                                             CylI  protein (cylI) Cellular processes                           6.76 Down 
sag0673                                                                                CylK protein (cylK) Cellular processes                           5.98 Down 
sag2043                          cAMP factor (cfb)                                             Cellular processes                           5.76 Down 
sag1733        Universal stress protein 
family                                        
Cellular processes                           96.38 Up 
sag0777              ATP- dependent RNA 
helicase                                            
Transcription          21.94 Up 
sag1216  Pullulanase (sap) Energy metabolism 20.61 Down 
sag0856  Glycogen synthase (glgA) Energy metabolism   20.31 Down 
sag1907   Keto-hydroxyglutarate-
aldolase (eda-2) 
Amino acids 
biosynthesis 
48.04 Down 
sag2165  Ornithine 
carbamoyltransferase 
(argF-2) 
Amino acids 
biosynthesis 
10.84 Down 
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Figure 4.1 Differential regulation of gene expression in GBS strain 2603V/R after exposure to 
absence or presence of 1% glucose. Genes were classified into 17 functional categories. Bars 
indicate the number of genes differentially regulated in the absence versus presence of glucose. 
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Figure 4.2 Differential regulation of gene expression in GBS strain 2603 V/R versus the isogenic 
csrRS mutant strain after incubation in medium with 1% glucose versus a sugars-free complex 
medium. White bars indicate the number of glucose-regulated genes in the wild-type strain; black 
bars indicate the number of genes that are glucose- dependent and CsrR- dependent; grey bars 
indicate the number of genes that are glucose-dependent and CsrRS-independent. 
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4.4 Glucose influences the BibA exposure on cell wall surface 
Recently in our group, a well-conserved, cell wall–anchored protein that we refer 
to as GBS immunogenic bacterial adhesin, or BibA, was identified (Santi et al., 
2007). BibA is immunogenic in humans and confers resistance to phagocytic 
killing, thus contributing to GBS survival in human blood (Santi et al., 2007). bibA 
expression is modulated by the CsrRS two-component regulatory system, which 
regulates the expression of genes encoding known virulence factors, such as β-
hemolysin (Lamy et al., 2004; Jiang et al., 2008). Lamy et al. have recently shown 
that bibA is up-regulated in a ΔcsrRS mutant strain (Lamy et al., 2004). 
Furthermore, Santi et al. reported that bibA is down-regulated when GBS is 
grown at acidic pH and they confirmed a CsrRS dependent regulation in response 
to such environmental factor (Santi et al., 2009a). 
To investigate the role of glucose in bibA regulation, we performed a comparative 
gene expression analysis growing the bacteria in presence of this sugar and we 
found a down regulation of gene expression (2.4 fold). Further analysis of the 
transcript by real time PCR confirmed the data observed in microarray experiment 
(2.1 fold). 
To further confirm that glucose has a repressor effect on BibA protein expression 
we performed a western blot analysis. For this reason we analyzed the TCA 
precipitated surnatants from bacterial growth after exposure to glucose. Western 
blot analysis clearly showed that BibA expression was highly reduced in high 
glucose conditions (data not shown). The bacteria were also analyzed by FACS 
analysis using an anti-BibA antiserum to detect the protein presence on bacterial 
50 
 
surface. As reported in figure 4.3, BibA surface expression was down-regulated 
following bacteria transition from a medium without glucose (blue line) to a 
medium with high glucose content (green line). 
 
 
 
 
Figure 4.3 Flow cytometry analysis of 2603V/R strain grow in CM in the absence (blue line 
histogram) and presence of glucose (green line histogram) incubated with a polyclonal mouse 
anti-BibA antibody and stained with PE-conjugated anti-rabbit IgG antibody. The red histogram 
indicates bacteria treated only with secondary antibody. 
51 
 
4.5 CsrR specifically binds to the bibA promoter 
Lamy and colleagues (Lamy et al., 2004) identified a potential CsrR recognition 
sequence, through DNase I footprinting and sequence comparisons of upstream 
regions from three genes, including bibA gene from NEM 316 strain (gbs2018). A 
comparison of the DNA regions protected by CsrR from DNase I cleavage 
allowed to identify a highly conserved nonanucleotide motif 5’-TATTTTAAT-3’. 
This sequence is 100% conserved in the CsrR binding regions of the cylX and 
bibA promoters. For bibA gene, two binding sites for CsrR were identified at -60 
bp and -144 bp from translational starting point.  
Based on these evidences, we analyzed the bibA promoter in 2603 V/R strain 
and found a putative CsrR binding site at -146 bp from translational starting point 
(Fig. 4.4). 
To better define CsrRS-mediated gene regulation, we deeper investigated its 
mechanism of action on bibA expression. To determine whether CsrR interacts 
directly with the bibA promoter region, we performed electrophoresis mobility shift 
assay (EMSA) using recombinant CsrR protein. A biotin-DNA probe, which 
corresponded to the promoter region of bibA, was incubated with increasing 
concentrations of CsrR. As shown in figure 4.5A, CsrR induced a shift in the 
mobility of the fragment at a concentration of 0.8 μg, postulating that bibA 
expression could be controlled by this two component system.  
As already described, CsrS is the sensor kinase protein of the CsrRS TCS 
responsible for the phosphorylation of the regulator component (CsrR) at a 
conserved aspartate residue. Aspartate phosphorylation usually alters the effector 
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activity by modulating DNA binding affinity and as a consequence, controlling of 
gene expression. 
Recently, Jiang and colleagues (Jiang et al., 2008) demonstrated that 
phosphorylation of CsrR on aspartate, increases its affinity to promoters of 
different genes. To understand the relevance of CsrR phosphorylation in bibA 
regulation, we performed in vitro EMSA using a chemically phosphorylated CsrR 
through acetyl-phosphate.  This modification leads to an increased affinity of 
CsrR for the bibA promoter, as testified by the observation of a shift of PbibA 
band already when 0.6 μg of recombinant CsrR were added (Fig. 4.5A). 
To verify the specificity of CsrR binding to the bibA promoter, we performed a 
competitive EMSA by adding a 250-fold or 500-fold excess of unlabelled probes 
corresponding to the bibA promoter or a non-correlated promoter (sag0017). As 
displayed in figure 4.5B, the addition of the unlabelled bibA promoter (lanes 3-4) 
impaired the binding of recombinant CsrR to the PbibA biotin probe, while the 
presence of a non specific competitor did not have any effect (lanes 5-6). These 
data confirm the capability of CsrR to specifically bind the bibA promoter and that 
CsrR phosphorilation increases the affinity for the DNA region corresponding to 
the bibA promoter. 
 
5’ATAATAGATTATTTTAGATAGAAACAACCCAAACCCTTAGATTTTACTAAGGGTTTTTTGTGT
GGAAAATAACATATATATCCGATTAAATTATAAAAAAATAATCTTTTGATTATTTTTACTAGATT
GTTGAGCAAAAAAACATTAAAAAAAAGATGTTTATTTTAATAAAATGTAAATAAATTAAAGAAAA
GTGTTGAAATAAAAAACTCCAAGTTATATAATTAGTTAAGGAACTCAAATTAAATTAAAATAAAC
GTGGTCCTATCCTAATAAATTAGGATTTTCAACTAACTATATAAAGGAGCGAATATG3 
Figure 4.4 Intragenic region between nucleotides 2045046 - 2045361 (Reverse Strand) The 
potential CsrR binding site is highlighted in red. The underline region is the first translated codon. 
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Figure 4.5 A)The bibA promoter (1 ng) was incubated with different amounts of purified CsrR and 
phosphorylated CsrR. B) Unlabeled bibA and sag0017 promoters were tested for their ability to 
sequester CsrR from biotin-labeled bibA promoter (1 ng). Lane1: labelled PbibA. Lane 2: CsrR 
(0.8 µg) incubated with labelled PbibA. Lane 3-4: Competition assay with PbibA (250x-500x) as 
specific competitor. Lane 5-6: Competition assay with Psag0017 as non specific competitor (250x-
500x). In three experiments the protein-DNA complexes were separated on a native 6% 
polyacrylamide gel. 
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4.6 CsrR acts as repressor of bibA expression 
These data by postulating a direct interaction between CsrR and the bibA 
promoter suggest that CsrR controls the expression of this gene in vivo.  
To investigate how the presence of glucose can influence the role of CsrR in bibA 
expression we performed chromatin immuno-precipitation (ChIP) analysis. 
Bacterial cultures grown to an OD600 of 0.5 were exposed for 30’ to glucose and 
in vivo cross-linked with formaldehyde. After sonication, protein-DNA complexes 
were immunoprecipitated with a nonsaturating amount of polyclonal CsrR 
antiserum. The immunoprecipitated DNA (IP) was analyzed by dot blot analysis, 
spotting on membrane the IP and flowthrough (FT) and using 32P-labelled bibA 
promoter as probe. FT samples indicated that the DNA amount loaded in each 
spot was comparable (data do not shown). As shown in figure 4.6, quantification 
of dot blot intensity relative to DNA immunoprecipitated with CsrR antiserum 
revealed a 3 fold increase in the amount of 32P-labelled bibA promoter in GBS 
cultures grown in high glucose (1%) medium compared to sugar-free conditions. 
The same experiment was performed using an isogenic ΔcsrRS deletion mutant 
and no differences in the magnitude of immunoprecipated DNA were observed 
(data not shown). 
These data strongly postulate that CsrR acts as a repressor of bibA expression in 
vivo. 
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Figure 4.6 Comparison of 
32
P-labelled bibA promoter levels immunoprecipitated with a CsrR 
antiserum in 2603 V/R wild type strain grown in medium devoid of glucose (0) or in the presence of 
1% glucose (1) (n=3). **, P ≤ 0.01. Error bars represent the SD. n indicates the number of 
independent experiments. 
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4.7 Promoter region of sap gene shows the CcpA binding site 
In addition to genes that appeared to be glucose and CsrRS dependent, we found 
a large group of genes (63%), involved in GBS metabolism, transport and protein 
synthesis, that was modulated by glucose both in the wild-type strain and in the 
csrRS mutant strain, indicating that their expression was glucose dependent but 
CsrRS independent.  
GBS, as other streptococcal species (Tomoyasu et al., 2010; Abranches et al., 
2008), has a complex metabolic system that controls carbohydrate catabolism, 
named CcpA regulatory system, in which enzymes necessary for the metabolism 
of alternative sugar are inhibited in the presence of glucose. In particular, CcpA, 
under the stimuli of environmental sugars, regulates the expression of metabolic 
genes and virulence determinants (Tomoyasu et al., 2010; Abranches et al., 
2008; Almengor et al., 2007). Genes subjected to CcpA regulation are identifiable 
by the presence of a target DNA sequence, called the catabolite-responsive 
element (cre) site, to which CcpA binds. 
To investigate the presence of the cre box in the promoter region of GBS genes, 
we performed a bioinformatic analysis of the 2603 V/R genome using the 
program Reg Precise 
(http://regprecise.lbl.gov/RegPrecise/gmregulon.jsp?gmproject_id=6875). By this 
comparative analysis we found that in 2603 V/R strain, 60 operons, conteining 
139 genes showed an identical sequence as the one recognized by CcpA. In 
particular, we found that 77% of them were differentially regulated in the presence 
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of glucose, strengthening the hypothesis that CcpA may have a role in their 
regulation. Streptococcal pullulanases are metabolic enzymes with a glycosidic 
hydrolase activity towards α-glucan polysaccharides and are considered key 
extracellular components in bacterial metabolism. One of the most regulated 
gene under high glucose experimental conditions is sap, recently demonstrated to 
encode for a GBS pullulanase enzyme capable to catabolize complex sugars and 
to induce functional antibodies (Santi et al., 2008). In particular, SAP is affected 
by presence of glucose and resulted to be highly down regulated (20 fold) when 
bacteria were grown with this sugar. Of importance, microarray analysis 
comparing 2603 V/R WT strain and an isogenic ΔcsrRS mutant strain, revealed 
that sap was still highly down-regulated, indicating that this modulation was 
independent from this two component system. 
Analysis of sap promoter (Nucleotides 1226300 - 1226469 Reverse Strand) with 
the program DBTBS (http://dbtbs.hgc.jp/) revealed that this region carries a 
putative cre box, placed between -65 bp and -52 bp from the starting +1bp and 
displaying a 5’ TGCAAGCGCTTGC 3’ sequence relative to the cre consensus 
sequence (Fig. 4.7) as described in the literature (Tomoyasu et al., 2010).  
 
 
 
 
 
 
. 
 
5’AGGAAATTTTTGATAAAAAAGCTAGGCAATATTGCTTAGCTTTTTTGTAATGCTATTGATAGT
TTTAGTGAAAATTTCAAAAAAATAAAGAAATCATTTACTTGTTGCAAGCGCTTGCGTAAATTGT
TATGATTTTATTGGTAACAATTCATTAAAAAAGGAGAATGATA 3’ 
Figure 4.7 Intragenic region between nucleotides 1226300 - 1226469 (Reverse Strand). The 
potential CcpA binding site is highlighted in red. 
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4.8 CcpA is able to recognize the sap promoter 
The test the ability of recombinant CcpA to bind the sap promoter, we performed 
an EMSA. For this analysis two PCR-generated DNA fragments were 
synthesized: one relative to the promoter of the sap gene, containing a cre site 
and a second one, the bibA promoter, which does not display a canonical binding 
motif for CcpA. Both DNA fragments were separately incubated in buffer Z with 4 
different amounts of CcpA and loaded on 1% agarose gel. As shown in Fig. 4.8, 
after electrophoresis of the reaction mixtures, we observed that both regions, 
(bibA promoter, lanes 1-5; sap promoter, lanes 6-10), were shifted by the 
presence of recombinant CcpA protein. However, for the promoter containing the 
cre box, a bandshift was observed already at 2 μg of recombinant CcpA (lane 8), 
while a retardation band for bibA was observed only at 4 μg (lane 5). These data 
suggest that CcpA has a general affinity for DNA sequences, but it binds the cre 
motif with a higher affinity: in fact a lower amount of protein is required for gel 
retardation with sap. 
 
Figure 4.8 The bibA promoter (25 
ng, Lanes 1 to 5) and the sap 
promoter (25 ng, Lanes 6 to 10), 
were incubated with two different 
amounts of purified CcpA (1 µg, 
Lanes 2 and 7; 2 µg, Lanes 3 and 8; 
3 µg, Lanes 4 and 9; 4 µg, Lanes 5 
and 10). 
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4.9 CcpA binds specifically the promoter of pullulanase 
To assess whether the recombinant protein CcpA could bind the cre box in 
pullulanase promoter, EMSA was performed with CcpA using, as probe, biotin-
labeled DNA fragment, corresponding to the cre site from the sap promoter (cre 
box, Table 3.1). The probe was incubated with different concentration of 
recombinant protein and the complex was resolved on native polyacrylamide gel. 
The lower amount of CcpA able to induce the mobility retardation of the probe 
was 0.6 μg (data do not shown).  
After establishing the minimum concentration at which the shift was observed, we 
performed EMSA using biotin-labeled DNA fragments, carrying both a wild type 
and a mutated cre sequence (mutated cre, Table 3.1). Figure 4.9A shows that 
recombinant CcpA was able to induce a shift in mobility of the cre box probe, 
while it was not able to bind the fragment carrying a mutated cre sequence. 
CcpA specific binding to the cre sequence was also tested by competition EMSA. 
As competitors, unlabeled wild type and mutated cre sequences were used. As 
shown in Fig. 4.9B CcpA binding to labelled cre box sequence was reversed 
when either a 100-fold or 500-fold excess of unlabelled sap cre sequence was 
added, while it was not affected by competition with identical concentrations of a 
mutated cre sequence.  
In conclusion, we postulate that recombinant CcpA is able to bind the cre box 
present in the promoter of pullulanase in a specific manner. Indeed, CcpA does 
not recognize a mutated cre sequence. The competition assay has also 
demonstrated that an unlabeled wild type cre box probe, but not the mutated one, 
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competes for the binding to the protein, enforcing the specific affinity of CcpA for 
this sequence. These results suggest that the sap gene could be directly 
regulated by CcpA, and its repression observed under high glucose conditions 
depending on this regulator. 
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Figure 4.9 A) The sap cre (1 ng, Lanes 1 to 3) and the mutated cre probes (1 ng, Lanes 4 to 6), 
were incubated with two different amounts of purified CcpA. 
B) Unlabeled sap cre and mutated cre fragment were tested for their ability to sequester CcpA 
from biotin-labeled sap cre probe (1 ng). Lane 1: CcpA (1.5 µg) incubated with labelled sap cre. 
Lane 2-3: Competition assay with sap cre (100x-500x) as specific competitor. Lane 4-5: 
Competition assay with mutated cre as non specific competitor (100x-500x). In three experiments 
the protein-DNA complexes were separated on a native 6% polyacrylamide gel. 
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5. Discussion 
Diabetes mellitus is characterized by inappropriately high concentrations of 
glucose in plasma as a result of a relative or absolute lack of insulin. Patients with 
uncontrolled diabetes mellitus can be more susceptible to bacterial infections, 
which can lead to higher morbidity and mortality than in healthy, non-diabetic 
patients because of dysfunction in polymorphonuclear neutrophil bactericidal 
function, cellular immunity, and complement activation. For this reason, diabetic 
patients tend to have a higher incidence and increased severity of infections than 
non-diabetic patients.  
Short and transient periods of hyperglycaemia result in abnormalitiesin 
granulocyte adherence, chemotaxis, phagocytosis, and bactericidal function. 
These impairments in immune function have been associated with an increased 
risk of infections. Systemic hyperglycaemia results in derangement of the immune 
system including neutrophil function, cellular immunity, and complement function.  
As previous studies have shown, Klebsiella pneumoniae, followed by 
Streptococcus spp. were the most commonly isolated organisms among diabetic 
patients, whereas in the non-diabetic group Streptococcus spp., followed by 
Staphylococcus spp., were most common (Zheng et al., 2012 ). 
Although GBS is commonly associated with neonatal diseases and postpartum 
infections, it is also an important cause of morbidity and mortality among adults. 
GBS infection has been reported to occur in adults with serious underlying 
conditions and, in particular, diabetes has been reported to be one of the most 
important risk factor promoting GBS infections. Patients with diabetes display 
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peripheral neuropathy or peripheral vascular diseases following trauma, 
particularly to the lower extremities. GBS takes advantage of this condition by 
crossing the endothelial barrier and promoting bacterial invasion of the foot. 
Indeed, GBS is also found in biopsy of patients with foot infections, a common 
status of patients suffering from diabetes. The impact of hyperglycemia upon 
susceptibility to GBS infection has not been fully elucidated, but, at least in part, 
this effect seems to be due to impairment of neutrophil effector functions. Indeed, 
Mazade et al. have reported that high glucose levels impair neutrophil-mediated 
phagocytosis and killing of GBS and reduce superoxide production thus ensuring 
spreading of infection (Mazade and Edwards, 2001). 
Although clinical evidences indicate a strong correlation between individuals with 
high blood glucose levels and the propensity to acquire GBS systemic infections, 
the signaling events triggered in this bacterium by high glucose conditions and 
the relative modulation of the expression of virulence determinants are still 
unknown.  
Glucose concentration in blood varies since 80 mg/dL in healthy people until 600 
mg/dL in diabetic patients with severe complications. A clinical study has reported 
a patient admitted in hospital with blood glucose concentration of 1288 mg/dL 
(Yanai et al., 2012) that corresponds to ~1% of sugar. To investigate the 
adaptation of GBS to high glucose presence, we performed a gene expression 
analysis growing bacteria in the absence and presence of this carbon source. 
One of the limitation for setting in vitro experiments looking at the effect of carbon 
sources on bacteria stress response is the fact that metabolites generated during 
the incubation of bacteria with sugars can alter the pH of the milieu and, 
differently from what happens in vivo, where the environment (i.e. blood) is rapidly 
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buffered, may dramatically affect the activation of intracellular pathways. In order 
to precisely delineate the impact of glucose, we defined that the duration of the 
experiments was limited to 30 minutes, a time point at which pH was still constant 
as at the initial conditions (data not shown). 
We found that glucose affected transcription of ~30% of genes; in particular the 
most highly regulated genes belong to transport and binding proteins and 
metabolism families.  
Recent reports have clearly elucidated the molecular mechanisms by which GBS 
adapts to different environmental conditions, including pH, carbon source 
availability, biological fluids and temperature (Mereghetti et al., 2009; Sitkiewicz et 
al., 2009; Santi et al., 2009). During these events a wide range of genes involved 
in adhesion to the host, nutrient acquisition and survival to the immune system 
are differently modulated. For example, global gene expression analysis of GBS 
grown in amniotic fluid, blood and pH stress conditions has revealed a number of 
mechanisms used by this bacterium to adapt to the host. Our study proposes that 
a general trend of adaptive regulation is triggered during the growth of GBS in the 
hyperglycemic milieu of the blood, as for diabetic patients. In particular, we 
observed that, at a gene expression level, GBS quickly adapts to environmental 
carbon sources changes by modulating both transcription and translation of 
genes involved in transport, metabolism and virulence.  
One intriguing finding of our analysis is that the exposure of GBS to glucose 
stress conditions appears to down-regulate several virulence factors, suggesting 
that in such a scenario these determinants may be dispensable to bacterial 
invasiveness. In this context, genes encoding for pore-forming toxins, such as 
hemolysin β and CAMP factor, both known to be crucial in promoting cell invasion 
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and lysis (Pritzlaff et al., 2001; Lang et al., 2003), were found to be highly down-
regulated. Furthermore, the presence of glucose reduced the transcription of 
genes involved in host cell adherence, such as Lmb (Spellerberg et al., 1999) and 
serum resistance, such as bibA (Santi et al., 2009). 
The down-regulation of virulence determinants in a high glucose milieu clearly 
point out the reliance of GBS fitness on the access to the metabolites derived by 
the catabolism of carbon sources. Indeed, over the past few years it has been 
reported that catabolism of carbohydrates plays a key role in the pathogenesis of 
invasive streptoccocci, including Streptococccus pneumoniae, Streptococcus 
pyogenes and GBS (Almengor et al., 2007; Shelburne et al., 2008a; iyer and 
Camilli, 2007; Jones et al., 2000). Johns and colleagues have recently applied 
signature-tagged transposon mutagenesis to a neonatal sepsis model and 
showed the importance of carbohydrate catabolism for GBS infectivity (Jones et 
al., 2000). In particular, by knocking out genes involved in complex carbohydrate 
metabolism, including a maltose-binding protein (mal), a phosphotransferase 
(PTS) and a sucrose hydrolase (scrB), they observed an attenuated virulence 
(Jones et al., 2000). Furthermore these genes, which clearly impact GBS 
virulence, were also found to be down-regulated in our study, suggesting a direct 
link between the modulation of genes coding for virulence factors and the one 
responsible for carbohydrate utilization, leading to an attenuated status of 
bacteria. Indeed, virulence is an energy consuming condition and bacteria 
occupying carbohydrate-rich niches, such as the blood of hyperglycemic 
individuals, may avoid the activation of virulence-associated pathways.  
Response of GBS to variations in environment relies on two major types of 
transcriptional regulators, the two-component gene regulatory systems (TCS) and 
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stand-alone regulators (such as CcpA). The best characterized TCS in 
streptococci is the CsrR/S system, which plays a key role in connecting the 
expression of complex carbohydrate metabolism genes together with that of 
virulence factors, thereby contributing pathogenesis (Lamy et al., 2004; 
Churchward, 2007; Mascher et al., 2003). In our study a wide range of glucose-
dependent genes, in particular factors implicated in GBS transposon function and 
virulence, resulted to be under CsrRS regulation, strongly suggesting that 
effectors of this TCS are involved in the response and adaptation of GBS to high 
glucose condition. As previously reported for the response of GBS to pH stress 
conditions (Santi et al., 2009), also in the case of high glucose conditions the 
contribution of CsrRS to the transcription of glucose-dependent genes was found 
to be independent on CsrR abundance, as its expression remained constant 
along the time span of the experiment. This is in agreement with our findings 
showing that CsrR enhances its affinity for the bibA promoter in the presence of 
glucose. Based on these evidences, we speculate that as for the pH-dependent 
activation of CsrR (Santi et al., 2009), the transmission of a signal through the 
CsrS sensor protein during glucose-stress conditions, may be responsible for the 
increased affinity for regulated promoters (Jiang et al., 2008).  
The clearest link between complex carbohydrate utilization and virulence factor 
production is represented by the transcriptional regulator CcpA, exhaustively 
studied in GAS (Almengor et al., 2007; Shelburne et al., 2008b), but also present 
in other streptococcal species (Tomoyasu et al., 2010; Abranches et al., 2008). 
This complex metabolic system controls carbohydrate catabolism by inhibiting 
enzymes necessary for the metabolism of alternative sugar in the presence of 
glucose. In particular, CcpA, under the stimuli of environmental sugars, 
67 
 
modulates both metabolic and virulence genes by binding to the cre site and 
repressing their expression (Tomoyasu et al., 2010; Abranches et al., 2008; 
Almengor et al., 2007). In our study, we demonstrated that the cre box-containing 
promoter of sap, one of the most regulated genes in the presence of glucose, is a 
target of CcpA in vitro, suggesting that this protein may contribute to the 
regulation of metabolic genes under glucose stress conditions. Indeed, we found 
that numerous genes reported to be potentially controlled by CcpA were among 
the most down-regulated under high glucose conditions. These data might a 
starting point for future investigations to better define the role of carbon 
catabolism in GBS virulence. 
The need for an increased knowledge of bacterial pathogenesis to better design 
curative strategies is among the most challenging objective of modern society. In 
this context, the data reported in this paper by highlighting mechanisms used by 
GBS to adapt to pathological conditions, may contribute to the understanding of 
GBS infectivity and put the basis for the development of next generation 
therapeutic and preventive agents. 
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